We celebrate the success stories of GLP-1s, but we rarely talk about the crash that follows when treatment stops. And it’s not just psychological. The body rebounds fast—hunger, weight, and metabolic chaos rush back in.
The problem isn’t the medication itself. It’s that we’ve built an elegant on-ramp for GLP-1s—and almost no off-ramp at all.
The data couldn’t be clearer. In the STEP-1 extension trial, participants who stopped semaglutide regained roughly two-thirds of the weight they had lost within one year. Their blood pressure, cholesterol, and blood-sugar levels slid back toward baseline.
…
The implication is simple: for most patients, GLP-1s are not a 12-week intervention—they’re chronic therapy.
Yet in real life, chronic use isn’t always realistic.
Insurance coverage ends. Supplies run short. A job changes, or a deductible resets.
…
Share this article
And what follows looks less like a gentle decline than a metabolic whiplash. Appetite returns fast—but satiety signals lag.
…
The question isn’t whether GLP-1s “work.” They clearly do—while they’re in use. The real question is whether our healthcare system can support the “after”.
